BioSpace News Archive

Cerus Corporation (Nasdaq: CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2022, as well as key clinical and corporate developments.

Donghoon Lee, CEO of SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing treatments for central nervous system disorders and beyond, recognized the team for their achievements, thanked them for their commitment to the epilepsy community, and shared his vision for SK Life Science, Inc. and its anti-seizure medication.

Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) today announced positive results of a final analysis of overall survival (“OS”) from the pivotal study JUPITER-02 (NCT03581786), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab in combination with gemcitabine and cisplatin as the first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (“NPC”).

GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors

Hospital for Special Surgery announced that Douglas E. Padgett, MD will be appointed Surgeon-in-Chief and Medical Director when Bryan T. Kelly, who has held those positions since 2019, transitions to Chief Executive Officer later this year.

Bavarian Nordic A/S announced that it has entered into an agreement with Emergent BioSolutions Inc. to acquire two marketed travel vaccines, Vivotif® for the prevention of typhoid fever and Vaxchora® against cholera as well as a Phase 3 vaccine candidate for the prevention of Chikungunya virus for a total consideration of up to USD 380 million, including USD 270 million in an upfront payment and up to USD 110 million in future conditional milestone payments.

Cytovation ASA announces that the first patient has been dosed in its Phase 2a study investigating CyPep-1 monotherapy in patients with advanced melanoma refractory to checkpoint inhibitors.

Taiwan-based Formosa Pharmaceuticals announced that the company has entered into a collaboration agreement with Eyenovia, Inc. for the development of novel ophthalmic therapeutics.

Gamma Biosciences announced that it has entered into an agreement with Swedish life sciences company Biotage AB, whereby Biotage will acquire Gamma’s operating company, Astrea Bioseparations, in exchange for newly issued shares in Biotage, creating a global chromatography leader with an attractive mix of products and services across multiple end-markets globally.